Delcath Systems, Inc. Announces Additional $35M In Funding Tied To FDA Approval of HEPZATO KIT
Portfolio Pulse from Bill Haddad
Delcath Systems, Inc. has announced an additional $35M in funding, which is tied to the FDA approval of their HEPZATO KIT.
September 01, 2023 | 6:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Delcath Systems, Inc. has secured an additional $35M in funding following the FDA approval of their HEPZATO KIT, which could potentially boost their financial position and stock price.
The additional funding of $35M tied to the FDA approval of HEPZATO KIT is a positive development for Delcath Systems. This could strengthen their financial position and potentially lead to an increase in their stock price in the short term. The news is highly relevant and important for DCTH investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100